Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma.
about
Consensus on the role of human cytomegalovirus in glioblastomaImmunotherapy for cancer in the central nervous system: Current and future directionsAdvances in the treatment of newly diagnosed glioblastomaDevelopment of targeted therapies in treatment of glioblastomaCurrent vaccine trials in glioblastoma: a reviewMalignant gliomas: current perspectives in diagnosis, treatment, and early response assessment using advanced quantitative imaging methodsImmunotherapy advances for glioblastomaAn update on vaccine therapy and other immunotherapeutic approaches for glioblastomaA phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study.Immunotherapy of Malignant Tumors in the Brain: How Different from Other Sites?Prospects of immune checkpoint modulators in the treatment of glioblastomaCurrent Therapeutic Advances Targeting EGFR and EGFRvIII in GlioblastomaMicheliolide derivative DMAMCL inhibits glioma cell growth in vitro and in vivoA pilot study of IL-2Rα blockade during lymphopenia depletes regulatory T-cells and correlates with enhanced immunity in patients with glioblastomaDCVax®-L--developed by Northwest BiotherapeuticsHistory and current state of immunotherapy in glioma and brain metastasis.An EGFRvIII-targeted bispecific T-cell engager overcomes limitations of the standard of care for glioblastoma.Single vs. combination immunotherapeutic strategies for glioma.Recognition and killing of autologous, primary glioblastoma tumor cells by human cytomegalovirus pp65-specific cytotoxic T cells.Metabolic targeting of EGFRvIII/PDK1 axis in temozolomide resistant glioblastoma.Evolution of malignant glioma treatment: from chemotherapy to vaccines to viruses.The indoleamine 2,3-dioxygenase pathway controls complement-dependent enhancement of chemo-radiation therapy against murine glioblastoma.Epidermal growth factor receptor and variant III targeted immunotherapy.Manipulation of Innate and Adaptive Immunity through Cancer Vaccines.Myeloablative temozolomide enhances CD8⁺ T-cell responses to vaccine and is required for efficacy against brain tumors in mice.Intratumoral temozolomide synergizes with immunotherapy in a T cell-dependent fashion.Immunosuppression in patients with high-grade gliomas treated with radiation and temozolomideMonoclonal antibody blockade of IL-2 receptor α during lymphopenia selectively depletes regulatory T cells in mice and humans.Combined Flt3L/TK gene therapy induces immunological surveillance which mediates an immune response against a surrogate brain tumor neoantigen.Victory and defeat in the induction of a therapeutic response through vaccine therapy for human and canine brain tumors: a review of the state of the art.The evolution of the EGFRvIII (rindopepimut) immunotherapy for glioblastoma multiforme patientsImmunotherapy for neuro-oncology: the critical rationale for combinatorial therapy.Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma.Impact of temozolomide on immune response during malignant glioma chemotherapyPD-L1 expression and prognostic impact in glioblastoma.Vaccine injection site matters: qualitative and quantitative defects in CD8 T cells primed as a function of proximity to the tumor in a murine glioma modelSerum elevation of B lymphocyte stimulator does not increase regulatory B cells in glioblastoma patients undergoing immunotherapy.Unique biology of gliomas: challenges and opportunities.The natural killer cell response and tumor debulking are associated with prolonged survival in recurrent glioblastoma patients receiving dendritic cells loaded with autologous tumor lysates.Profound impairment of adaptive immune responses by alkylating chemotherapy
P2860
Q24632103-3FB96A9F-5366-4B28-BBB2-140BABFF7B96Q26750765-84D0778C-6779-4920-8641-C13FEF530D72Q26773514-F8D6C3DC-7208-4564-BE29-44623B7C3DA6Q26778787-5B8211A2-DEFE-47F1-91B1-377149BAA7A4Q26828965-536C3B2B-C803-4001-A4A4-E5D3CA99DD4BQ26853516-80E551A4-9506-486C-A52D-D8FBF7812CACQ26866513-5C40BBEC-AC1C-4694-B406-2CD280A4B53DQ27024830-34D74A65-92EC-4C41-8C88-5F542DD88A45Q27853118-E1C8D86C-45BE-47F3-AAC3-4C28B7F92C55Q28078539-A573E39E-4F0F-4F06-BD87-3E6A0A8A01A7Q28081371-E41E5B9E-BBCF-475D-BCCB-1A120E033694Q28087306-937DCEEC-C585-4F25-A237-D2E9BD9A8B78Q28543364-FC24E389-696D-4F18-B610-FB5639A7FAF4Q28731711-8DA5B518-CDDE-4BF3-8612-75A1144E3256Q30875456-AABD9D54-F561-4559-A6EB-5E8093D3E044Q33656811-FC35503A-4E26-4A38-A8DE-95AD884251EFQ33665884-907BFA9B-AF0C-4F5D-92D7-8EC2878D4A75Q33746041-8525E1C3-5B8F-4891-8978-8FDCD5D1CAF0Q33761585-E2711D82-724E-4C7D-8BA7-FE145D5F8332Q33829265-37E45A2C-DBD0-49B6-8608-8B7E6916A5E5Q33923950-07B0DDC5-30DE-435C-A9CC-7D527E678123Q33929529-D6BDA60E-AA2F-4DC5-8757-C22DF6D31E14Q34391942-F138F0D1-C8FE-441B-92CE-4209A6E7C8FBQ34552791-DE57FCE9-620B-46CF-90B5-1127888365E6Q34634616-F1BED429-8FC6-4709-BA3D-779D47B9F06EQ34775318-9DCAB32F-EF79-4BEB-ADC9-775A2F18AE7EQ35167257-A40C5418-5013-4D99-B3B1-8E97F745E745Q35220386-5CDA56FB-BCB6-48C4-AF32-070DDE70976BQ35285859-0C6B8548-729E-4C84-A173-511D2E5883D8Q35799695-3ACBB471-03EF-4465-9D56-971828BD5771Q35886554-047EB07C-B741-496D-9DB5-5AA65489224AQ36224057-3E1A65A3-FC2B-4361-9ABC-C170DAB90F35Q36248008-8756FB72-FEF0-424F-AEE9-BCE7725CAC55Q36362798-2573BC64-3E72-4A08-9AD2-BD52EBE5EF2BQ36493843-DD46D099-6D9C-49ED-8C6E-17D5232676BFQ36514324-56527E33-3E34-49FE-844E-A15205FB7EC3Q36558234-90EC4F77-6B56-4BB6-8838-19E95C3869AEQ36626214-E51968C1-BFE6-4927-82A2-F9F2C719DD06Q36866151-F32DC165-C9AE-401A-80C7-A9A3B1952F2DQ36922577-805C9550-005F-4043-82B0-8794D679A6AA
P2860
Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma.
description
2010 nî lūn-bûn
@nan
2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
name
Greater chemotherapy-induced l ...... in patients with glioblastoma.
@ast
Greater chemotherapy-induced l ...... in patients with glioblastoma.
@en
Greater chemotherapy-induced l ...... in patients with glioblastoma.
@nl
type
label
Greater chemotherapy-induced l ...... in patients with glioblastoma.
@ast
Greater chemotherapy-induced l ...... in patients with glioblastoma.
@en
Greater chemotherapy-induced l ...... in patients with glioblastoma.
@nl
prefLabel
Greater chemotherapy-induced l ...... in patients with glioblastoma.
@ast
Greater chemotherapy-induced l ...... in patients with glioblastoma.
@en
Greater chemotherapy-induced l ...... in patients with glioblastoma.
@nl
P2093
P2860
P50
P356
P1433
P1476
Greater chemotherapy-induced l ...... in patients with glioblastoma.
@en
P2093
Amy B Heimberger
April Coan
Duane A Mitchell
Gary E Archer
James E Herndon
James J Vredenburgh
John H Sampson
Kenneth D Aldape
Mark R Gilbert
Raymond Sawaya
P2860
P304
P356
10.1093/NEUONC/NOQ157
P50
P577
2010-12-10T00:00:00Z